supp.ai
Discover Supplement-Drug Interactions
Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago
supplement:
Phenethyl Isothiocyanate
drug:
Paclitaxel
Research Papers that Mention the Interaction
“In this context, the combination of a drug that induces a strong mitotic arrest, such as paclitaxel , with another that inhibits slippage, such as PEITC , translates into increased apoptotic induction.”
Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction“By Western blotting analysis, treatment of MCF7 cells with both PEITC and taxol led to a 10.4-fold and 5.96-fold increase in specific acetylation of alpha-tubulin over single agent PEITC and taxol, respectively.”
“Combination of phenethyl isothiocyanate (PEITC) and paclitaxel (taxol) has been shown to work synergistically to increase apoptosis and cell cycle arrest in breast cancer cells.”
“In this report, we further explored the mechanisms for the synergistic activity of PEITC and taxol in MCF7 and MDA-MB-231 (MB) breast cancer cell lines.”
“The combination of PEITC and taxol also reduced expressions of cell cycle regulator Cdk1, and anti-apoptotic protein bcl-2, enhanced expression of Bax and cleavage of PARP proteins.”
Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells“In conclusion, the combination of PEITC and taxol exhibits a synergistic effect on growth inhibition in breast cancer cells.”
“The combination of PEITC and taxol significantly decreased the IC50 of PEITC and taxol over each agent alone.”
“This study examined whether combining paclitaxel (taxol) with a novel epigenetic agent phenethyl isothiocyanate (PEITC) will yield a synergistic effect on inhibiting breast cancer cells.”
Help us improve supp.ai, we'd love to hear your feedback: Submit Feedback